NSABP FC-6: Phase II Study to Determine Surgical Conversion Rate in Patients (pts) Receiving Neoadjuvant (NA) mFOLFOX7 Plus Dose-escalating Cetuximab (C) for Unresectable K-RAS Wild-type (WT) Colorectal Cancer with Metastases (mCRC) Confined to the Liver

被引：0
|
作者：
Wagman, L. D. [1 ,2 ]
Geller, D. A. [3 ,4 ]
Jacobs, S. A. [5 ,6 ]
Petrelli, N. J. [7 ,8 ]
Allegra, C. J. [7 ,9 ]
Buyse, M. [10 ]
Wolmark, N. [11 ,12 ]
O'Connell, M. J. [11 ]
机构：
[1] Natl Surg Adjuvant Breast & Bowel Project NSABP, Orange, CA USA
[2] St Joseph Hosp, Orange, CA USA
[3] NSABP, Pittsburgh, PA USA
[4] Univ Pittsburgh, Med Ctr, UPMC Liver Canc Ctr, Pittsburgh, PA USA
[5] Univ Pittsburgh, Sch Med, NSABP, Pittsburgh, PA USA
[6] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA USA
[7] NSABP, Newark, DE USA
[8] Helen F Graham Canc Ctr, Christiana Care Hlth Serv, Newark, DE USA
[9] Univ Florida, Gainesville, FL USA
[10] Int Inst Drug Dev, Brussels, Belgium
[11] NSABP, Pittsburgh, PA USA
[12] Allegheny Gen Hosp, Allegheny Canc Ctr, Pittsburgh, PA 15212 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2014年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 9 条
  • [1] NSABP FC-6: Surgical conversion rate in colorectal cancer patients with unresectable, KRAS wild-type liver metastases receiving mFOLFOX7 plus cetuximab
    Wagman, Lawrence D.
    Geller, David A.
    Jacobs, Samuel A.
    Petrelli, Nicholas J.
    Allegra, Carmen J.
    Lipchik, Corey
    Pogue-Geile, Katherine L.
    Srinivasan, Ashok
    Wang, Ying
    O'Connell, Michael J.
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (08) : 1494 - 1503
  • [2] Phase II study to determine surgical conversion rate in patients receiving neoadjuvant mFOLFOX7 plus cetuximab for unresectable wild-type KRAS colorectal cancer with metastases confined to liver
    Jacobs, S. A.
    Allegra, C. J.
    Wagman, L. D.
    Geller, D. A.
    O'Connell, M. J.
    Buyse, M. E.
    Wolmark, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] PEAK: A randomized phase II study to compare the efficacy of panitumumab plus mFOLFOX6 to bevacizumab plus mFOLFOX6 in patients (pts) with previously untreated, unresectable metastatic colorectal cancer (mCRC) expressing wild-type KRAS
    Schwartzberg, L. S.
    Wagner, V. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Prognostic factors in KRAS wild-type (wt) metastatic colorectal cancer (mCRC) patients (pts) treated with biweekly cetuximab (C) plus irinotecan, fluorouracil, and leucovorin (FOLFIRI): A phase II study
    Personeni, Nicola
    Rimassa, Lorenza
    Verusio, Claudio
    Barni, Sandro
    Destro, Annarita
    Raschioni, Carlotta
    Armenia, Silvia
    Floriani, Irene
    Gerardi, Chiara
    Monteforte, Marta
    Villa, Eugenio
    Bozzarelli, Silvia
    Roncalli, Massimo
    Torri, Valter
    Labianca, Roberto
    Santoro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
    Jacobs, Samuel A.
    George, Thomas J.
    Kolevska, Tatjana
    Wade, James Lloyd
    Zera, Richard
    Buchschacher, Gary L.
    Al Baghdadi, Tareq
    Shipstone, Asheesh
    Lin, Daniel
    Yothers, Greg
    Pogue-Geile, Katherine L.
    Huggins-Puhalla, Shannon Leigh
    Allegra, Carmen Joseph
    Wolmark, Norman
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Panitumumab (P) plus FOLFIRINOX or mFOLFOX6 in unresectable metastatic colorectal cancer (mCRC) patients (pts) with RAS/BRAF wild-type (WT) tumor status from circulating DNA (cirDNA): First results of the randomised phase II PANIRINOX-UCGI28 study
    Mazard, T.
    Ghiringhelli, F.
    Winter, A.
    De la Fouchardiere, C.
    Botsen, D.
    Andre, T.
    Vanbockstael, J.
    Dos Santos, M.
    Martin-Babau, J.
    Rinaldi, Y.
    Evesque, L.
    Ellis, S.
    Gavoille, C.
    Smith, D.
    Fonck, M.
    Sefrioui, D.
    Pezzella, V.
    Nougaret, S.
    Thierry, A. R.
    Bouche, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1270 - S1270
  • [7] PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC)
    Steven Schwartzberg, Lee
    Rivera, Fernando
    Karthaus, Meinolf
    Fasola, Gianpiero
    Canon, Jean-Luc
    Yu, Hua
    Go, William Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [8] NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status-Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).
    Jacobs, Samuel A.
    Lee, James J.
    George, Thomas J.
    Yothers, Greg
    Kolevska, Tatjana
    Yost, Kathleen J.
    Wade, James Lloyd
    Buchschacher, Gary L.
    Stella, Philip J.
    Shipstone, Asheesh
    Pogue-Geile, Katherine L.
    Srinivasan, Ashok
    Lucas, Peter C.
    Allegra, Carmen Joseph
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6-A GEMCAD study.
    Maurel, J.
    Garcia-Albeniz, X.
    Mendez Mendez, C.
    Martin-Richard, M.
    Pericay, C.
    Vera, R.
    Aparicio, J.
    Rubini, M.
    Cuatrecasas, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
1